Document is current
Any future updates will be listed below
-
Authors
Nonaka, Kyosuke
Maruko, Ichiro https://orcid.org/0000-0001-5647-6372
Kakehashi, Mizuha
Kawai, Moeko
Hasegawa, Taiji
Iida, Tomohiro
- License Information
-
More Information
Article History
Received: 22 April 2024
Revised: 26 October 2024
Accepted: 5 November 2024
First Online: 22 November 2024
Declarations
:
: The procedures used conformed to the tenets of the Declaration of Helsinki and were approved by the Institutional Review Board of the Tokyo Women’s Medical University.
: Dr. Nonaka has nothing to disclose. Dr. Maruko receives lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, and Nikon. He holds a patent. Dr. Kakehashi has nothing to disclose. Dr. Kawai has nothing to disclose. Dr. Hasegawa receives lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Alcon Pharma, Santen, Kowa, Senju Pharmaceutical, R.E. Medical, Nikon Health Care Japan, JFC Sales Plan, Otsuka Pharmaceutical, and Japan Beringer Ingelheim. Dr. Iida receives grants from Nidek, Topcon, Santen, Novartis Pharma, Senju Pharmaceutical, Japan Alcon, HOYA, and AMO, consultant fees from Bayer Pharmaceuticals, Novartis Pharma, Chugai Pharmaceutical, Japan Beringer Ingelheim, and Janssen Pharma, and received lecturing and travel fees from Bayer Pharmaceuticals, Novartis Pharma, Japan Alcon, Santen, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, Otsuka Pharmaceutical, Nikon, and Kyowa Kirin. He holds a patent.
: .
